Trainee Accountant

Our pipeline includes more than 30 programs in oncology, immunology and neuroscience. Clinical trials run at hundreds of sites, managed by our clinical operations group and CRO partners.

Position summary:

We are backfilling a position after an internal move. Expect extra hours during year-end close and audit fieldwork in January and February. The Trainee Accountant handles month-end close tasks, journal entries and account reconciliations for a multi-entity company. Our headquarters is in Las Cruces, and about a third of the team works remotely from other countries. You will be employed through our employer-of-record partner in Australia, with a local contract and salary paid in local currency. You will need at least 4 hours of overlap with US Central time. You will write a lot of updates, so clear written English is important.

Main duties:

• Document close procedures and keep the close checklist current.
• Prepare and post monthly journal entries for accruals, prepaids and allocations.
• Reconcile balance sheet accounts, including cash, fixed assets and accrued liabilities.
• Investigate P&L variances and explain them to the Controller.
• Maintain the general ledger in NetSuite or Sage Intacct.
• Process intercompany transactions and eliminations across three entities.
• Track prepaid expenses and amortization schedules.

Qualifications:

• 0-2 years of general ledger or public accounting experience.
• Comfortable explaining numbers to non-accountants.
• Organised and accurate under deadlines.
• Strong Excel: XLOOKUP or VLOOKUP, pivot tables, SUMIFS.

Preferred qualifications:

• ASC 842 lease accounting.
• Public accounting audit background.
• FloQast or BlackLine experience.
• Power BI or Tableau.

Pay: $54,000 - $74,000 per year

Benefits:

• Annual salary review.
• 20 days paid time off.
• Paid parental leave.
• Wellness allowance.
• Public holidays observed per your country.

Start: Immediately.

Demo job created on 11jobs for testing and demonstrations. It is not an actual opening at Ingleby Therapeutics.